“Start low, go slow.” Geriatric pharmacology texts and recent systematic reviews (e.g., on dosing of oncology drugs) warn ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results